Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor–positive Breast Cancer

The high frequency of aberrant PI3K pathway activation in hormone receptor–positive (HR(+)) breast cancer has led to the development, clinical testing, and approval of the p110α-selective PI3K inhibitor alpelisib. The limited clinical efficacy of alpelisib and other PI3K inhibitors is partially attr...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Robert B., Farhi, Jonathan, Adams, Miranda, Parwani, Kiran K., Cooper, Garrett W., Zecevic, Milica, Lee, Richard S., Hong, Andrew L., Spangle, Jennifer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036132/
https://www.ncbi.nlm.nih.gov/pubmed/36970726
http://dx.doi.org/10.1158/2767-9764.CRC-22-0158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036132/
https://www.ncbi.nlm.nih.gov/pubmed/36970726
http://dx.doi.org/10.1158/2767-9764.CRC-22-0158

Ejemplares similares